Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRDM-16
- Development stage
- Preclinical
- Lead developer
- ARIZ Precision Medicine
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
PRDM-16 is an early-stage therapeutic candidate being developed by ARIZ Precision Medicine for the treatment of leukemia. It is designed to target PRDM16 (PR domain zinc finger protein 16), a member of the PRDM family of epigenetic regulators that is often dysregulated or rearranged in myeloid malignancies, such as acute myeloid leukemia (AML). The drug likely utilizes ARIZ's proprietary siRNA platform to inhibit the expression of PRDM16, thereby disrupting the maintenance of leukemic stem cells and inhibiting tumor growth. The program is currently in the early stages of development, with the next planned milestone being in vitro proof-of-concept (POP) studies to validate its efficacy.
02
Targets
RISC (RNA-induced silencing complex)PRDM16 (PR domain zinc finger protein 16)
Beyond the preview
Go deeper on PRDM-16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRDM-16.